Hospital
Baylor Medical Center at Irving
Baylor Medical Center at Irving was paid $13.27M by Medicaid between Dec 2019 and Dec 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 64% of everything it billed.
33Billing provider infoBAYLOR MEDICAL CENTER AT IRVING
IRVING, TX 75061
IRVING, TX 75061
33aNPI1992700983assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.27M
24GClaims218,784
24DCodes billed105
24AFirst – last monthDec 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#12 of 109
Median peer was paid$1.15M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 148 | $1K | |
| 2020 | 7,818 | $201K | |
| 2021 | 51,713 | $2.93M | |
| 2022 | 69,151 | $5.52M | |
| 2023 | 57,632 | $3.13M | |
| 2024incomplete | 32,322 | $1.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 64% | 30,115 | 28,300 | $8.53M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 19,467 | 18,168 | $999K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 3,073 | 2,852 | $856K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 10,524 | 9,894 | $499K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.0% | 6,218 | 5,917 | $395K |
| 80053 | Comprehensive metabolic panel | 1.8% | 15,119 | 13,188 | $233K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 5,005 | 4,558 | $154K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 16,430 | 14,148 | $152K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 5,526 | 4,833 | $147K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 783 | 708 | $127K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 924 | 851 | $112K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,030 | 1,925 | $108K |
93 more codes
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 202 | $108K |
| 81025 | <1% | 8,145 | $81K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,067 | $62K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,846 | $58K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,522 | $56K |
| 81001 | <1% | 9,644 | $50K | |
| 76801 | <1% | 623 | $50K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,080 | $49K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 648 | $43K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 726 | $43K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,041 | $37K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 942 | $31K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,896 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,049 | $20K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 285 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 263 | $19K |
| 84484 | <1% | 3,218 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 565 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 565 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 722 | $14K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 349 | $12K |
| 83880 | <1% | 1,175 | $12K | |
| 84702 | <1% | 1,302 | $11K | |
| 87486 | <1% | 202 | $10K | |
| 87581 | <1% | 202 | $10K | |
| 83690 | <1% | 2,715 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 202 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 427 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,093 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,042 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 838 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,903 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 55 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,256 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 44 | $3K |
| 85027 | <1% | 844 | $3K | |
| 81003 | <1% | 1,709 | $3K | |
| 87210 | <1% | 596 | $3K | |
| 85730 | <1% | 1,252 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $2K |
| 83735 | <1% | 985 | $2K | |
| 85610 | <1% | 1,464 | $2K | |
| 86900 | <1% | 959 | $2K | |
| 83605 | <1% | 452 | $2K | |
| 86901 | <1% | 915 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 935 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 702 | $1K |
| 82330 | <1% | 975 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,192 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 111 | $878.19 |
| 84703 | <1% | 170 | $869.40 | |
| 85007 | <1% | 387 | $846.91 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,023 | $613.38 |
| 84030 | <1% | 89 | $609.56 | |
| 94760 | <1% | 71 | $539.21 | |
| 84132 | <1% | 1,064 | $536.45 | |
| 86850 | <1% | 72 | $477.64 | |
| 84145 | <1% | 40 | $466.23 | |
| 74018 | <1% | 17 | $452.23 | |
| 87040 | <1% | 64 | $446.47 | |
| 73630 | <1% | 30 | $444.36 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $424.98 |
| 73030 | <1% | 27 | $420.97 | |
| 82565 | <1% | 1,008 | $390.01 | |
| 82947 | <1% | 962 | $389.81 | |
| 84295 | <1% | 899 | $322.43 | |
| 85014 | <1% | 848 | $307.15 | |
| 82435 | <1% | 920 | $298.12 | |
| 84520 | <1% | 876 | $270.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 463 | $270.22 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $240.26 |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 23 | $238.90 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 398 | $208.78 |
| 82948 | <1% | 33 | $168.82 | |
| 86140 | <1% | 78 | $155.00 | |
| 96376 | <1% | 22 | $145.50 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 55 | $137.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 344 | $131.41 |
| 85379 | <1% | 27 | $117.81 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $54.07 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 70 | $42.87 |
| 82962 | <1% | 1,790 | $33.54 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 402 | $23.86 |
| 87186 | <1% | 20 | $20.73 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 12 | $9.03 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 27 | $9.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 32 | $1.11 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 114 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 12 | $0.00 |
| 36416 | 0% | 16 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 30 | $0.00 |
| 80047 | 0% | 21 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,988 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHAMP, CINDY (CEO)